FDA Approves Ibrutinib For Patients With Previously Treated Chronic Lymphocytic Leukemia


In February 2014 the U.S. Food and Drug Administration (FDA) approved ibrutinib as a treatment for patients with chronic lymphocytic leukemia (CLL). This approval is a significant advancement for patients with this blood cancer. LLS funding has supported clinical trials and laboratory studies of ibrutinib for patients with CLL, MCL and other lymphomas. Ibrutinib is now a possible treatment for patients with mantle cell lymphoma (MCL) and CLL who have received at least one prior treatment.

Ibrutinib, which goes by the trade name ImbruvicaTM, is a therapy that targets an enzyme which promotes growth of a variety of B-cell cancers, including CLL, MCL, Waldenstrom’s macroglobulinemia (WM), follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), hairy cell leukemia (HCL) and multiple myeloma.

To find out more about the FDA’s approval of ibrutinib or for more information on this treatment option visit the LLS News Room article here.

-Submitted by Ana Hurtado, Boston Light The Night Walk walker and Hodgkin’s survivor


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s